Skip to content

Dr. Lili Li

227
Dr. Lili Li
李力力
Share
qualifications
Ph.D., M.B.
rank
Research Associate Professor
orcid
0000-0002-0292-5889
email
lili_li@cuhk.edu.hk

Specific Research / Sites of Interest


  1. Cell signaling perturbation through epigenetic disruption of cancer genes in human cancers

  2. Post- translational modifications of signaling regulatory proteins during carcinogenesis

  3. Viral-induced epigenetic reprogramming in the pathogenesis of Epstein-Barr virus (EBV)

Short Biography

Dr. Li obtained her Ph.D. degree in 2007 at Xiangya School of Medicine, Central South University, China. She did her postdoctoral training at the State Key Laboratory of Oncology in South China, Department of Clinical Oncology, the Chinese University of Hong Kong from 2009 to 2013. She was appointed as Research Assistant Professor in 2014 and later Research Associate Professor (2020) in the Department of Clinical Oncology, CUHK.

She has published ~100 papers in international journals (total citations: >4700; h-index: 43) including Cell Death & Differentiation, CCR, Oncogene, and Cell Res. She was awarded an Outstanding Scientific Research Achievement Award in Natural Science of the Institutions of Higher Education (MoE). She also got a Natural Science Award in Hunan Province. She is a reviewer for the China NSFC and multiple scientific journals. She is an Editorial board member of Clinical Epigenetics and Epigenomes, and a Young Board member of the China Association of Pathophysiology.

Most Representative Publications

1. Li L*, Shu XS, Geng H, Ying J, Guo L, Luo J, Xiang T, Wu L, Ma BBY, Chan ATC, Zhu X, Ambinder RF, Tao Q* (*corresp author). A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/ activation and promoting autophagy. Cell Death Differ. 2023 Feb 23. doi: 10.1038/s41418-023-01129-w
2. Ying Y, Wang M, Chen Y, Li M, Ma C, Zhang J, Huang X, Jia M, Zeng J, Wang Y, Li L, Wang X, Tao Q, Shu XS. Zinc finger protein 280C contributes to colorectal tumorigenesis by maintaining epigenetic repression at H3K27me3-marked loci. Proc Natl Acad Sci U S A. 2022 May 1;119(22):e2120633119
3. Wong KC, Hui EP, Lo KW, Lam WK, Johnson D, Li L, Tao Q, Chan KC, To KF, King AD, Ma BB, Chan AT. Nasopharyngeal Carcinoma: An Evolving Paradigm. Nature Reviews Clin Oncol. 2021; 18:679-695.
4. Tao C, Luo J, Tang J, Zhou D, Feng S, Qiu Z, Putti TC, Xiang T, Tao Q, Li L*, Ren G* (*corresp author). The tumor suppressor Zinc finger protein 471 suppresses breast cancer growth and metastasis through inhibiting AKT and Wnt/β-catenin signaling. Clin Epigenetics. 2020 Nov 17; 12(1):173.
5. Li L*, Fan Y, Huang X, Luo J, Zhong L, Shu XS, Lu L, Xiang T, Chan AT, Yeo W, Chen C, Chan WY, Huganir RL, Tao Q* (corresp author). Tumor suppression of Ras GTPase activating protein RASA5 antagonizing Ras signaling perturbation in human carcinomas. iScience. 2019; 21:1-18.
6. Li L, Xu J, Qiu G, Ying J, Du Z, Xiang T, Wong KY, Srivastava G, Zhu XF, Mok TS, Chan AT, Chan FK, Ambinder RF, Tao Q. Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. Theranostics. 2018; 8(1):61-77.
7. Li L, Zhang Y, Fan Y, Sun K, Su X, Du Z, Tsao SW, Loh TK, Sun H, Chan AT, Zeng YX, Chan WY, Chan FK, Tao Q. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics. 2015; 7(2):155-73.
8. Li L, Ying J, Tong X, Zhong L, Su X, Xiang T, Shu X, Rong R, Xiong L, Li H, Chan AT, Ambinder RF, Guo Y, Tao Q. Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas. Cell Mol Life Sci. 2014; 71(11):2179-92.
9. Li L, Ying J, Li H, Zhang Y, Shu XS, Fan Y, Tan J, Cao Y, Tsao SW, Srivastava G, Chan AT, Tao Q. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through WNT/β-catenin signaling and silenced in common carcinomas. Oncogene. 2012; 31(34):3901-12.
10. Li L, Tao Q*, Jin H, van Hasselt A, Poon FF, Wang X, Zeng MS, Jia WH, Zeng YX, Chan AT*, Cao Y* (*corresp author). The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res. 2010; 16(11):2949-58.

Google Scholar

https://scholar.google.com.hk/citations?user=6lZzARsAAAAJ&hl=zh-TW&oi=ao